Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

Similar articles for PubMed (Select 23757355)

1.

Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study.

Cho EJ, Lee JH, Yoo JJ, Choi WM, Lee MJ, Cho Y, Lee DH, Lee YB, Kwon JH, Yu SJ, Lee JM, Suh KS, Kim K, Kim YJ, Yoon JH, Kim CY, Lee HS.

Clin Cancer Res. 2013 Aug 1;19(15):4218-27. doi: 10.1158/1078-0432.CCR-12-3443. Epub 2013 Jun 11.

2.

Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization.

Cho E, Kim HC, Lee JH, Jeong-Ju Yoo, Choi WM, Cho YY, Lee MJ, Cho Y, Lee DH, Lee YB, Yu SJ, Kim YJ, Yoon JH, Chung JW, Kim CY, Lee HS.

PLoS One. 2014 Mar 4;9(3):e90862. doi: 10.1371/journal.pone.0090862. eCollection 2014.

3.

Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.

Shao YY, Huang CC, Lin SD, Hsu CH, Cheng AL.

Clin Cancer Res. 2012 Jul 15;18(14):3992-7. doi: 10.1158/1078-0432.CCR-11-2853. Epub 2012 May 23.

4.

Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL.

J Clin Oncol. 2011 Oct 10;29(29):3892-9. doi: 10.1200/JCO.2011.36.0636. Epub 2011 Sep 12.

5.

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB.

J Hepatol. 2014 Feb;60(2):319-24. doi: 10.1016/j.jhep.2013.09.008. Epub 2013 Sep 14.

6.

Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection.

Zhu W, Guo L, Zhang B, Lou L, Lin Z, Zhu X, Ren N, Dong Q, Ye Q, Qin L.

Ann Surg Oncol. 2014 Apr;21(4):1304-13. doi: 10.1245/s10434-013-3445-0. Epub 2013 Dec 24.

PMID:
24366422
7.

Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma.

Ranke MB, Maier KP, Schweizer R, Stadler B, Schleicher S, Elmlinger MW, Flehmig B.

Horm Res. 2003;60(4):174-80.

PMID:
14530605
8.

The insulin-like growth factor-1 and expression of its binding protein‑3 in chronic hepatitis C and hepatocellular carcinoma.

Adamek A, Kasprzak A, Mikoś H, Przybyszewska W, Seraszek-Jaros A, Czajka A, Sterzyńska K, Mozer-Lisewska I.

Oncol Rep. 2013 Sep;30(3):1337-45. doi: 10.3892/or.2013.2546. Epub 2013 Jun 19.

PMID:
23784592
9.

Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.

Hyeon J, Ahn S, Lee JJ, Song DH, Park CK.

Dig Dis Sci. 2013 Jul;58(7):1916-22. doi: 10.1007/s10620-013-2609-x. Epub 2013 Mar 2.

PMID:
23456506
10.

Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.

Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, Waidmann O.

Eur J Cancer. 2013 Nov;49(16):3442-9. doi: 10.1016/j.ejca.2013.06.002. Epub 2013 Jun 26.

PMID:
23810247
11.

Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.

Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta GB, Caporaso N, Carella C.

Cancer. 2002 Dec 15;95(12):2539-45.

12.

Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.

Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, Diamandis EP.

Urology. 2001 Mar;57(3):471-5.

PMID:
11248622
14.

Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation.

Facciorusso A, Del Prete V, Antonino M, Neve V, Crucinio N, Di Leo A, Carr BI, Barone M.

J Gastroenterol Hepatol. 2014 Nov;29(11):1905-10. doi: 10.1111/jgh.12618.

PMID:
24731153
15.

Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery.

Zhu CB, Chen LL, Tian JJ, Su L, Wang C, Gai ZT, Du WJ, Ma GL.

Ann Surg Oncol. 2012 Mar;19(3):817-25. doi: 10.1245/s10434-011-2026-3. Epub 2011 Aug 23.

PMID:
21861215
16.

Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma.

Tsai JF, Jeng JE, Chuang LY, You HL, Wang LY, Hsieh MY, Chen SC, Chuang WL, Lin ZY, Yu ML, Dai CY.

Scand J Gastroenterol. 2005 Jan;40(1):68-75.

PMID:
15841717
17.
18.

The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection.

Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, Liu Y, Ye S, Ren Z.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S375-84. doi: 10.1245/s10434-011-1836-7. Epub 2011 Jun 17.

PMID:
21681378
19.

Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer.

Holdaway IM, Mason BH, Lethaby AE, Singh V, Harvey VJ, Thompson PI, Evans BD.

ANZ J Surg. 2003 Nov;73(11):905-8.

PMID:
14616567
20.

High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.

Lv Y, Wang W, Jia WD, Sun QK, Huang M, Zhou HC, Xia HH, Liu WB, Chen H, Sun SN, Xu GL.

Eur J Surg Oncol. 2013 Oct;39(10):1129-35. doi: 10.1016/j.ejso.2013.06.023. Epub 2013 Jul 31.

PMID:
23916473
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk